The researchers further demonstrated that silencing of TRAM2 blocked the malignant progression of glioma by inhibiting the PI3K/Akt/mTOR signaling, rendering it a pathway with therapeutic potential (17). This evidence concerns the gene AKT1 and central nervous system cancer.